DE10299042I2 - Verwendung von Tetrahydrocarbazolderivaten als 5HT1-Rezeptor-agonisten. - Google Patents

Verwendung von Tetrahydrocarbazolderivaten als 5HT1-Rezeptor-agonisten.

Info

Publication number
DE10299042I2
DE10299042I2 DE2002199042 DE10299042C DE10299042I2 DE 10299042 I2 DE10299042 I2 DE 10299042I2 DE 2002199042 DE2002199042 DE 2002199042 DE 10299042 C DE10299042 C DE 10299042C DE 10299042 I2 DE10299042 I2 DE 10299042I2
Authority
DE
Germany
Prior art keywords
receptor agonists
tetrahydrocarbazole derivatives
tetrahydrocarbazole
derivatives
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2002199042
Other languages
German (de)
English (en)
Other versions
DE10299042I1 (de
Inventor
Francis David Smithkline King
Laramie Mary Smithkline Gaster
Alberto Julio C O Smit Kaumann
Rodney Christopher C O S Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10299042(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE10299042I1 publication Critical patent/DE10299042I1/de
Application granted granted Critical
Publication of DE10299042I2 publication Critical patent/DE10299042I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE2002199042 1991-06-26 1992-06-17 Verwendung von Tetrahydrocarbazolderivaten als 5HT1-Rezeptor-agonisten. Active DE10299042I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments
PCT/GB1992/001082 WO1993000086A1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists

Publications (2)

Publication Number Publication Date
DE10299042I1 DE10299042I1 (de) 2003-02-20
DE10299042I2 true DE10299042I2 (de) 2005-02-03

Family

ID=10697363

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2002199042 Active DE10299042I2 (de) 1991-06-26 1992-06-17 Verwendung von Tetrahydrocarbazolderivaten als 5HT1-Rezeptor-agonisten.
DE69226953T Expired - Lifetime DE69226953T2 (de) 1991-06-26 1992-06-17 Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69226953T Expired - Lifetime DE69226953T2 (de) 1991-06-26 1992-06-17 Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten

Country Status (34)

Country Link
US (2) US5464864A (enExample)
EP (1) EP0591280B1 (enExample)
JP (1) JP3261502B2 (enExample)
KR (1) KR100251571B1 (enExample)
CN (1) CN1034072C (enExample)
AP (1) AP344A (enExample)
AT (1) ATE170746T1 (enExample)
BR (2) BR9206237A (enExample)
CA (1) CA2113726C (enExample)
CZ (3) CZ282327B6 (enExample)
DE (2) DE10299042I2 (enExample)
DK (1) DK0591280T3 (enExample)
FI (1) FI103967B1 (enExample)
GB (1) GB9113802D0 (enExample)
HU (1) HU218907B (enExample)
IE (1) IE922062A1 (enExample)
IL (4) IL117105A0 (enExample)
LU (1) LU90939I2 (enExample)
MA (1) MA22563A1 (enExample)
MX (1) MX9203444A (enExample)
NL (1) NL300103I2 (enExample)
NO (2) NO304774B1 (enExample)
NZ (1) NZ243288A (enExample)
PL (3) PL171034B1 (enExample)
PT (1) PT100620B (enExample)
RU (1) RU2137474C1 (enExample)
SA (1) SA92130141B1 (enExample)
SG (1) SG47877A1 (enExample)
SI (1) SI9200125B (enExample)
SK (3) SK280907B6 (enExample)
TW (1) TW214544B (enExample)
UA (1) UA41254C2 (enExample)
WO (1) WO1993000086A1 (enExample)
ZA (1) ZA924658B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
ES2291503T3 (es) * 2001-09-28 2008-03-01 F. Hoffmann-La Roche Ag Formas pseudopolimorficas de carvedilol.
DE60317333T2 (de) 2002-06-21 2008-08-28 Suven Life Sciences Ltd. Tetracyklische arylsulfonylindole mit affinität zum serotonin rezeptor
MXPA04012834A (es) 2002-06-21 2005-04-25 Suven Life Sciences Ltd Arilalquil indoles novedosos que tienen afinidad por el receptor de la serotonina, utiles como agentes terapeuticos, proceso para su preparacion y composiciones farmaceuticas que los contienen.
SI1567492T1 (sl) 2002-11-28 2013-07-31 Suven Life Sciences Limited N-arilsulfonil-3-aminoalkoksiindoli
MXPA05005701A (es) 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil indoles sustituidos en la posicion 3 que tienen afinidad por el receptor de la serotonina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
WO2004055026A1 (en) 2002-12-18 2004-07-01 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity
RU2430088C2 (ru) * 2004-07-14 2011-09-27 Центарис Гмбх Производные тетрагидрокарбазола и фармацевтическая композиция на их основе
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
WO2008017989A1 (en) * 2006-08-07 2008-02-14 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
ES2538082T3 (es) 2007-02-11 2015-06-17 Map Pharmaceuticals Inc Método de administración terapéutica de DHE para permitir el rápido alivio de migraña mientras que se minimiza el perfil de efectos secundarios
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2011050140A1 (en) 2009-10-22 2011-04-28 Blue Fury Consulting, L.L.C. Posterior cervical fusion system and techniques
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
ES2751388T3 (es) 2011-07-22 2020-03-31 Univ Chicago IGF-1 para su uso en el tratamiento de la jaqueca
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
EP2816030A1 (en) 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
WO2025038666A2 (en) * 2023-08-13 2025-02-20 GATC Health Corp Compounds and methods for treating addiction
CN119499195A (zh) * 2024-11-26 2025-02-25 青岛国信制药有限公司 一种快速吸收琥珀酸呋罗曲坦片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4172834A (en) 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
SG47877A1 (en) 1998-04-17
PL171034B1 (en) 1997-02-28
MA22563A1 (fr) 1992-12-31
IL102322A (en) 1997-09-30
NO934800L (no) 1993-12-23
NO934800D0 (no) 1993-12-23
IL117105A0 (en) 1996-06-18
ZA924658B (en) 1993-12-24
PT100620B (pt) 1999-01-29
PL169392B1 (pl) 1996-07-31
LU90939I2 (fr) 2002-09-24
FI103967B (fi) 1999-10-29
HUT68961A (en) 1995-08-28
CN1034072C (zh) 1997-02-19
AU1977592A (en) 1993-01-25
NO2005011I1 (no) 2005-05-18
BR9206237A (pt) 1995-04-11
TW214544B (enExample) 1993-10-11
NL300103I1 (nl) 2002-12-02
NZ243288A (en) 1994-09-27
PT100620A (pt) 1993-09-30
JP3261502B2 (ja) 2002-03-04
NO304774B1 (no) 1999-02-15
AU652842B2 (en) 1994-09-08
SA92130141B1 (ar) 2005-12-18
AP9200403A0 (en) 1992-07-31
CN1069726A (zh) 1993-03-10
IL102322A0 (en) 1993-01-14
ATE170746T1 (de) 1998-09-15
CZ282083B6 (cs) 1997-05-14
RU2137474C1 (ru) 1999-09-20
EP0591280B1 (en) 1998-09-09
CA2113726C (en) 2008-02-19
CZ282061B6 (cs) 1997-05-14
HU218907B (hu) 2000-12-28
KR100251571B1 (ko) 2000-07-01
DE10299042I1 (de) 2003-02-20
UA41254C2 (uk) 2001-09-17
SK280906B6 (sk) 2000-09-12
AP344A (en) 1994-07-05
US5637611A (en) 1997-06-10
DE69226953T2 (de) 1999-05-12
SI9200125B (en) 2001-12-31
PL169410B1 (pl) 1996-07-31
JPH06508827A (ja) 1994-10-06
CZ150696A3 (en) 1997-06-11
SK131993A3 (en) 1994-06-08
HK1014669A1 (en) 1999-09-30
NL300103I2 (nl) 2003-02-03
SK280905B6 (sk) 2000-09-12
US5464864A (en) 1995-11-07
CZ286193A3 (en) 1994-07-13
BR1100460A (pt) 2000-07-18
MX9203444A (es) 1993-12-01
CZ150596A3 (en) 1997-05-14
SK280907B6 (sk) 2000-09-12
IL117104A0 (en) 1996-06-18
GB9113802D0 (en) 1991-08-14
CZ282327B6 (cs) 1997-06-11
WO1993000086A1 (en) 1993-01-07
FI103967B1 (fi) 1999-10-29
CA2113726A1 (en) 1993-01-07
FI935842A0 (fi) 1993-12-23
DE69226953D1 (de) 1998-10-15
IL117104A (en) 1997-09-30
FI935842A7 (fi) 1993-12-23
SI9200125A (en) 1992-12-31
EP0591280A1 (en) 1994-04-13
IE922062A1 (en) 1992-12-30
NO2005011I2 (no) 2008-02-11
DK0591280T3 (da) 1999-02-15
IL117105A (en) 1998-01-04

Similar Documents

Publication Publication Date Title
DE10299042I2 (de) Verwendung von Tetrahydrocarbazolderivaten als 5HT1-Rezeptor-agonisten.
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
FI914065A7 (fi) Serotoniini-5HT1A-agonisteja
KR950700906A (ko) 5-ht1 작동약으로서의 인돌 유도체(indole derivatives as 5-ht1 agonists)
DE68913022D1 (de) Heterozyklische Derivate.
DE69325167D1 (de) Kondensierte indol-derivate als 5-ht4-rezeptor-antagonisten
EP1048659A4 (en) RETINOID RECEPTOR AGONISTS
FI944805A7 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina
FI942635L (fi) Piperatsiinijohdannaiset 5HT1A-antagonisteina
ATE149163T1 (de) Indolin derivate als 5ht2c antagonisten
FI961628A0 (fi) Indolijohdannaisia NMDA-antagonisteina
ATE222492T1 (de) Verwendung von indolderivaten als 5ht1-agonisten
DE69418045D1 (de) Amidderivate als 5ht1d rezeptor antagonisten
DE69617995D1 (de) Indolalkylderivate von benzodioxanmenthylamin als 5-ht1a rezeptor liganden
DE69204290D1 (de) Verwendung von 1,2,2,3,3-pentafluorpropan.
DE59006366D1 (de) Substituierte Pyrazolinderivate.
DE69003213D1 (de) Imidazol-Derivate als Histamin-H3-Agonisten.
DE69320653D1 (de) Tetrahydrocarbazolderivate als 5-ht1-ähnliche agonisten
DE58903912D1 (de) Verwendung von 2-substituierten ethansulfonverbindungen als galvanotechnische hilfsstoffe.
FI923968A7 (fi) Heterosyklisesti substituoidut kinolyylimetoksifenyyliasetamidit
DE69100517D1 (de) Polyethyleneiminphosphonatderivate als Dispergiermittel enthaltende Zementzusammensetzungen.
FI915026A7 (fi) 2-(substituoitu pyrrolidinyylitio)karbapeneemijohdannaisia
DE3888727D1 (de) Verwendung von Äthylamin-Derivaten als antihypertensive Wirkstoffe.
FI915056A7 (fi) Substituoidut 1-(alkoksi-iminoalkyyli)imidatsoli-johdannaiset
FI912963A0 (fi) Hjaernverksamheten oekande pyrimidinylderivat.